Skip to main content
Erschienen in: Der Onkologe 9/2018

23.07.2018 | Zytostatische Therapie | Onkologiekongresse

ASCO – vom amerikanischen Krebskongress 2018

verfasst von: Dr. Annette Junker

Erschienen in: Die Onkologie | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Auszug

„Delivering Discoveries: Expanding the Reach of Precision Medicine“ hieß das Motto des 54. Jahreskongresses der American Society of Clinical Oncology (ASCO) vom 1. bis 5. Juni in Chicago: Die individualisierte Krebsmedizin muss allen Krebspatienten zugänglich sein. …
Literatur
1.
Zurück zum Zitat Tsimberidou AM et al (2018) Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period—The IMPACT study. J Clin Oncol 36(suppl; abstr LBA2553) Tsimberidou AM et al (2018) Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period—The IMPACT study. J Clin Oncol 36(suppl; abstr LBA2553)
2.
Zurück zum Zitat Schwark AL et al (2018) Pan-cancer microsatellite instability to predict for presence of Lynch syndrome. J Clin Oncol 36(suppl; abstr LBA1509) Schwark AL et al (2018) Pan-cancer microsatellite instability to predict for presence of Lynch syndrome. J Clin Oncol 36(suppl; abstr LBA1509)
3.
Zurück zum Zitat Earl HM et al (2018) PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4‑year (yr) disease-free survival (DFS) results. J Clin Oncol 36(suppl; abstr 506) Earl HM et al (2018) PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4‑year (yr) disease-free survival (DFS) results. J Clin Oncol 36(suppl; abstr 506)
4.
Zurück zum Zitat Sparano JA et al (2018) TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. J Clin Oncol 36(suppl; abstr LBA1) Sparano JA et al (2018) TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. J Clin Oncol 36(suppl; abstr LBA1)
5.
Zurück zum Zitat Mejean A et al (2018) CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial. J Clin Oncol 36 (suppl; abstr LBA3) Mejean A et al (2018) CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial. J Clin Oncol 36 (suppl; abstr LBA3)
7.
Zurück zum Zitat Lopes G et al (2018) Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1 %: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 36(suppl; abstr LBA4) Lopes G et al (2018) Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1 %: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 36(suppl; abstr LBA4)
8.
Zurück zum Zitat Pennell NA et al (2018) Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model. J Clin Oncol 36(suppl; abstr 9031) Pennell NA et al (2018) Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model. J Clin Oncol 36(suppl; abstr 9031)
9.
Zurück zum Zitat Yezefski T et al (2018) Comparison of chemotherapy use, cost, and survival in patients with metastatic colorectal cancer in Western Washington and British Columbia. J Clin Oncol 36(suppl; abstr LBA3579) Yezefski T et al (2018) Comparison of chemotherapy use, cost, and survival in patients with metastatic colorectal cancer in Western Washington and British Columbia. J Clin Oncol 36(suppl; abstr LBA3579)
10.
Zurück zum Zitat Mohile SG et al (2018) Improving communication with older patients with cancer using geriatric assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) cluster randomized controlled trial (CRCT). J Clin Oncol 36(suppl; abstr LBA10003) Mohile SG et al (2018) Improving communication with older patients with cancer using geriatric assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) cluster randomized controlled trial (CRCT). J Clin Oncol 36(suppl; abstr LBA10003)
Metadaten
Titel
ASCO – vom amerikanischen Krebskongress 2018
verfasst von
Dr. Annette Junker
Publikationsdatum
23.07.2018
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 9/2018
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-018-0434-8

Weitere Artikel der Ausgabe 9/2018

Der Onkologe 9/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.